Hugel Aesthetics Launches Direct US Sales Force for Letybo Neurotoxin

Hugel Aesthetics is launching a dedicated direct sales force and field-based medical affairs team in the United States to drive the adoption of its neurotoxin, Letybo (letibotulinumtoxinA-wlbg). For your practice, this means a shift to a hybrid sales model where you may interact with different representatives depending on your account size. While BENEV Company Inc will continue servicing its accounts, Hugel’s new direct team will focus on select strategic accounts throughout 2026. This transition brings more direct manufacturer support, training resources, and medical affairs backing if you want to integrate the toxin. Alongside the structural expansion, Hugel is introducing its "K-TOX" marketing campaign to highlight the product's history in South Korea, where it has been the top-selling neurotoxin for 10 consecutive years. Approved by the FDA in February 2024 and launched in the U.S. in March 2025, the 20-Unit dose toxin has a global track record of 44 million treatments across more than 70 countries. The increased corporate footprint suggests Hugel is preparing for an aggressive U.S. push, making it a highly leverageable time to negotiate opening orders or practice support.

Source: Morningstar, https://www.morningstar.com/news/pr-newswire/20260721la56811/hugel-aesthetics-announces-expansion-of-us-operations-to-drive-long-term-growth-and-adoption-of-letybo-letibotulinumtoxina-wlbg